• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the August 6, 2013 Meeting of the Cardiovascular and Renal Drugs Advisory Committee

 
Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance.
 
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information for the August 6, 2013 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF – 19.02MB)
 
Errata to the FDA Briefing Information for the August 6, 2013 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF – 191KB)
 
Errata 2 to the FDA Briefing Information for the August 6, 2013 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF – 15KB)
 
  
Bayer Healthcare Pharmaceuticals, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
 Bayer Briefing Information for the August 6, 2013 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF – 2.91MB)